Clinical Trials Logo

Hereditary Pancreatitis clinical trials

View clinical trials related to Hereditary Pancreatitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04743479 Recruiting - Diabetes Clinical Trials

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

ESPRIT-AI
Start date: December 1, 2020
Phase:
Study type: Observational

Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only ~6%[1]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed. Identifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, "Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.

NCT ID: NCT04095195 Recruiting - Lynch Syndrome Clinical Trials

Registry of Subjects at Risk of Pancreatic Cancer

IRFARPC
Start date: August 20, 2019
Phase:
Study type: Observational

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

NCT ID: NCT02309632 Withdrawn - Clinical trials for Pancreatic Neoplasms

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

Start date: November 2015
Phase: N/A
Study type: Interventional

100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years. This data will be used to determine the pancreatic cancer and precancerous lesion detection rate in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers or to biomarkers only.

NCT ID: NCT02206360 Active, not recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Early Detection Program

PCEDP
Start date: April 2014
Phase:
Study type: Observational [Patient Registry]

Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.

NCT ID: NCT02078245 Recruiting - Clinical trials for Hereditary Pancreatitis

Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.

Start date: August 2010
Phase:
Study type: Observational [Patient Registry]

Early detection of pre-cancerous lesions or early stage pancreatic cancer seems to have a positive impact in survival for patients with an increased genetic risk to develop pancreas cancer. In this study, following the indication of the swedish guidelines, consecutive patients with a family history for pancreas cancer underwent a clinical surveillance Magnetic Resonance Imaging (MRI) based. The results of this study were analyzed looking in the patients files collected during the screening period.